ClinicalTrials.gg
Not yet recruitingNCT04069286Updated Apr 29, 2024

EFFICACY OF ORAL AROEIRA (Schinus Terebinthifolia Raddi) COMPARED TO OMEPRAZOLE IN DYSPEPPSIA

A Phase 3 interventional study of Oral Aroeira and Omeprazole 20Mg Capsule in Dyspepsia, sponsored by Infan Industria Quimica Farmaceutica Nacional. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-29.

Sponsored by Infan Industria Quimica Farmaceutica Nacional · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
474
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a prospective, randomized, double - blind study of 474 male and female volunteers with dyspeppsia diagnosed at the Oswaldo Cruz University Hospital Gastroenterology Outpatient Clinic from March 2025 to March 2027.

Hypothesis:

As a non-inferiority study, the hypothesis is that the use of oral Aroeira (Schinus terebinthifolia Raddi) for the treatment of participants diagnosed with functional dyspepsia efficacy not inferior to therapy based on the use of omeprazole.

Read the detailed description

This is a prospective, randomized, double - blind study of 474 male and female volunteers with dyspeppsia diagnosed at the Oswaldo Cruz University Hospital Gastroenterology Outpatient Clinic from March 2025 to March 2027.

Hypothesis:

As a non-inferiority study, the hypothesis is that the use of oral Aroeira (Schinus terebinthifolia Raddi) for the treatment of participants diagnosed with functional dyspepsia efficacy not inferior to therapy based on the use of omeprazole.

The initial proposal of the project was a prospective, comparative and double blind study between aroeira and omeprazole together with antibiotic treatment for patients diagnosed with gastritis caused by Helicobacter pylori, whose dosage of aroeira (Schinus terebinthifolia Raddi) was 1 tablet of 640 mg, every 12 hours for 4 weeks and omeprazole was 1 capsule of 20 mg, 12/12h, for 4 weeks.

Due to Anvisa requirements, and taking into account the current rationale for gastritis related to this infection, we analyzed that a project with gastritis without the association with H. pylori would not be ideal. So, we are proposing a comparative study with the same drugs (aroeira versus omeprazole) in evaluating the complete relief of dyspeptic symptoms in Dyspepsia Functional. In this new proposal, the N will be 474 participants, maintaining a 1:1 ratio. Research participants will be those who report at least 1 of the 5 dyspeptic symptoms (nausea, heartburn, pain epigastric pain, abdominal discomfort aggravated/relieved by meals and feeling of early satiety) with onset more than 6 months, lasting at least 3 months and excluding other diagnoses by upper digestive endoscopy (EDA).

Our primary objective will be "Compare the effectiveness of oral mastic (Schinus terebinthifolia Raddi) versus omeprazole in relieving complete description of the symptoms of functional dyspepsia. The secondary objectives will be:

  1. Evaluate the improvement in the quality of life of participants with dyspeptic symptoms within each treatment (before and afterwards) and between aroeira versus omeprazole at the end of treatment;
  2. Evaluate complaints within each treatment (before and after) and between oral mastic versus omeprazole at the end of the treatment treatment;
  3. Evaluate possible adverse events to treatment with oral mastic versus omeprazole therapy reported by the participant.

Clinical Trial Protocol Oral Aroeira medicine (Schinus terebinthifolia Raddi) Version 03 of 14-June-2023 HB-F3-01/2019 Sponsor: INFAN - Indústria Química Farmacêutica Nacional S/A

The dosage of this study will be: 1 tablet of oral Aroeira (Schinus terebinthifolia Raddi) of 640mg, once a day, at least period of 4 weeks, and omeprazole, 1 capsule of 20mg, once a day, for a period of 4 weeks.

02

Conditions studied

  • Dyspepsia

Browse trials for

03

In context

Dyspepsia

372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.

This study's planned enrollment of 474 is above the median of 89 across 302 interventional studies indexed under Dyspepsia.

Browse Dyspepsia studies →

Lead sponsor

Infan Industria Quimica Farmaceutica Nacional is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

To be eligible to participate in this study, an individual must meet all of the following criteria:

Report of at least 1 of the 5 dyspeptic symptoms, with onset more than 6 months ago, with at least least 3 months in duration, according to the ROME IV Classification criteria:

  • Nausea;
  • Heartburn;
  • Epigastric pain;
  • Abdominal discomfort aggravated/relieved by meals;
  • Feeling of early satiety.

Manifestation of the desire to participate in the study in a free and informed manner.

Age range between 18 and 80 years old;

Ability and desire to use an acceptable method of listed below during the study and until the last follow-up visit:

  • Women - condoms, oral, topical, injectable or implantable contraceptive medications, Intrauterine Devices (IUDs) with or without hormones and true abstinence that is aligned with the participant's preferred and usual lifestyle (periodic abstinence [e.g., methods of table, ovulation, symptothermic, post-ovulation], declaration of abstinence during the period of study or coitus interruptus are not acceptable methods of true abstinence).
  • Women - will be referred to a gynecologist for screening and better definition of the method;
  • Men - guidance on condom use.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
474 participants (estimated)

Study arms

  • Experimental
    Treated Group

    Active Group with 237 participants undergoing treatment with oral mastic (Schinus terebinthifolia Raddi), 1 tablet of 640 mg + 1 placebo capsule, once a day, for a period of 4 weeks

    Drug: Oral Aroeira

  • Active comparator
    Control Group

    Comparator Group with 237 participants undergoing treatment with omeprazole, 1 20mg capsule + 1 placebo tablet, once a day, for a period of 4 weeks.

    Drug: Omeprazole 20Mg Capsule

Interventions

  • DrugOral Aroeira

    Active Group oral Aroeira (Schinus terebinthifolia Raddi), 1 tablet of 640 mg + 1 placebo capsule, once a day, for a period of 4 weeks.

  • Comparator Group omeprazole, 1 20mg capsule + 1 placebo tablet, once a day, for a period of 4 weeks.

06

What researchers measure

Primary outcomes

  1. Complete relief dyspeppsia symptom

    Assessment of the proportion of participants with complete relief of dyspeptic symptoms. Complete relief of symptoms will be considered if the scores obtained in items #3, #5 and #7 of the ROME III questionnaire are lower than or equal to their respective reference values for the diagnosis of each symptom of functional dyspepsia.

    Time frame: 30 days after the first day treatment

Secondary outcomes

  1. Life quality Improvement

    Assessment of the proportion of improvement in quality of life using the SF-36 quality of life questionnaire, taking into account the domains "Functional capacity", "Limitation due to physical aspects", "Pain", "General health status", "Vitality ", "Social aspects", "Emotional aspects" and "Mental health" generating a continuous numerical variable (between 0 and 100, where 0 is bad and 100 is good) corresponding to each domain.

    Time frame: 60 days after the first day treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Jul 2026, 16 months later.

Of 15 phase 3 interventional studies under Dyspepsia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's planned 16 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2019
First posted
Aug 28, 2019
StartEst.
Mar 2025
Primary completionEst.
Jul 2026
CompletionEst.
Mar 2027
Last update
Apr 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04069286
Lead sponsor
Infan Industria Quimica Farmaceutica Nacional
Collaborators
Hospital Universitário Oswaldo Cruz
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Mar 2025 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Apr 29, 2024

Study contacts

JAN CARLO MORAIS OLIVEIRA B DELORENZ, PhD
Contact
jancarlo@hebron.com.br
11989780869
Haliny Magalhães, Pharm. B.
Contact
haliny@hebron.com.br
Severino B Santos, PhD
principal investigator · Hospital Univeristário Oswaldo Cruz

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion